{"id":61121,"date":"2026-03-24T19:10:36","date_gmt":"2026-03-24T11:10:36","guid":{"rendered":"https:\/\/flcube.com\/?p=61121"},"modified":"2026-03-24T19:10:39","modified_gmt":"2026-03-24T11:10:39","slug":"tenacia-bio-licenses-ztalmy-to-golden-age-health-bain-backed-cns-specialist-partners-on-rare-epilepsy-drug-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61121","title":{"rendered":"Tenacia Bio Licenses Ztalmy to Golden Age Health \u2013 Bain-Backed CNS Specialist Partners on Rare Epilepsy Drug in China"},"content":{"rendered":"\n

Tenacia Biopharmaceuticals (Shanghai) Co., Ltd.<\/strong>, a Bain Capital-incubated CNS specialist<\/strong>, announced a licensing agreement<\/strong> with Golden Age Health Pte. Ltd. (GAH)<\/strong>, granting the Singapore-headquartered firm exclusive commercialization rights<\/strong> to Ztalmy (ganaxolone oral suspension)<\/strong> in mainland China<\/strong>. The neuroactive steroid<\/strong>, approved in China (July 2024)<\/strong> for CDKL5 deficiency disorder (CDD)-associated seizures<\/strong>, remains the first and only therapy<\/strong> for this rare epileptic encephalopathy affecting patients aged 2 years and older<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. (Bain Capital portfolio)<\/td><\/tr>
Licensee<\/strong><\/td>Golden Age Health Pte. Ltd. (GAH) \u2013 Singapore-headquartered<\/td><\/tr>
Asset<\/strong><\/td>Ztalmy (ganaxolone oral suspension)<\/td><\/tr>
Territory<\/strong><\/td>Mainland China<\/strong> (exclusive commercialization rights)<\/td><\/tr>
Original License<\/strong><\/td>Tenacia licensed from Marinus Pharmaceuticals<\/strong> for Greater China<\/td><\/tr>
China Approval<\/strong><\/td>July 2024<\/strong> \u2013 first and only approved therapy for CDD-associated seizures<\/td><\/tr>
Target Population<\/strong><\/td>Patients aged \u22652 years<\/strong> with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Context & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>CDKL5 Deficiency Disorder (CDD) Profile<\/th><\/tr><\/thead>
Genetic Basis<\/strong><\/td>Mutations in CDKL5 gene<\/strong> on X chromosome<\/td><\/tr>
Clinical Presentation<\/strong><\/td>Early-onset, refractory seizures<\/strong>; severe developmental delay<\/strong>; motor impairment<\/strong><\/td><\/tr>
Epidemiology<\/strong><\/td>Ultra-rare<\/strong> \u2013 estimated 1,000\u20132,000 diagnosed patients<\/strong> in China<\/td><\/tr>
Treatment Landscape<\/strong><\/td>No approved therapies prior to Ztalmy<\/strong>; standard of care = multiple antiepileptic drugs with limited efficacy<\/td><\/tr>
Mechanism<\/strong><\/td>Neuroactive steroid<\/strong> \u2013 positive allosteric modulator of GABA-A receptors; distinct from traditional AEDs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n
Tenacia Bio Perspective<\/th>Golden Age Health Perspective<\/th><\/tr><\/thead>
Commercial focus shift<\/strong> \u2013 partner with China distribution specialist while retaining development rights<\/td>Rare disease entry<\/strong> \u2013 exclusive rights to first-in-class asset in underserved market<\/td><\/tr>
Bain Capital portfolio optimization<\/strong> \u2013 monetize commercial rights; retain upside via milestones\/royalties<\/td>Neurology expertise<\/strong> \u2013 GAH CNS commercial infrastructure aligns with Ztalmy patient identification needs<\/td><\/tr>
Patient access acceleration<\/strong> \u2013 leverage GAH relationships with pediatric neurology centers<\/td>Orphan drug economics<\/strong> \u2013 premium pricing (~RMB 200,000\u2013300,000 annually) supports viable rare disease business model<\/td><\/tr>
Regulatory maintenance<\/strong> \u2013 Tenacia retains manufacturing\/importation responsibilities<\/td>First-mover advantage<\/strong> \u2013 2\u20133 year competitive lead before potential generics or biosimilars<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Commercial Outlook<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Rare Disease Policy<\/strong><\/td>National Rare Disease List (2018, 2023 expansions) supports reimbursement; CDD inclusion facilitates NRDL negotiation<\/td><\/tr>
Ztalmy Differentiation<\/strong><\/td>First and only approved CDD therapy<\/strong> in China; neuroactive steroid mechanism offers seizure reduction + neurodevelopmental benefits<\/strong><\/td><\/tr>
Patient Identification<\/strong><\/td>Genetic testing expansion in pediatric epilepsy centers critical for diagnosis; GAH medical education investment required<\/td><\/tr>
Revenue Potential<\/strong><\/td>Addressable market RMB 200\u2013400 million annually<\/strong> (500\u20131,000 treated patients \u00d7 RMB 200,000\u2013400,000 price); GAH break-even by Year 3<\/td><\/tr>
Tenacia Retained Rights<\/strong><\/td>Development and commercialization rights for other indications<\/strong> (e.g., tuberous sclerosis complex, Lennox-Gastaut syndrome)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n